Abstract: This invention refers to pharmaceutical compositions containing synergistic combinations of pentacyclic triterpenoids as active principles and denotes that some specific combinations between these types of drugs exhibit effects for the prevention or inhibition of viral infections. The compositions are found in specific quantities and proportions that enhance the pharmacological properties of the compounds, improving their bioavailability and pharmacokinetic properties, while reducing their toxicological and irritability effects, especially in the respiratory tract and the lungs.

Abstract: This invention refers to pharmaceutical compositions containing synergistic combinations of pentacyclic triterpenoids as active principles and denotes that some specific combinations between these types of drugs exhibit effects for the prevention or inhibition of viral infections. The compositions are found in specific quantities and proportions that enhance the pharmacological properties of the compounds, improving their bioavailability and pharmacokinetic properties, while reducing their toxicological and irritability effects, especially in the respiratory tract and the lungs.

Abstract: The invention refers to pharmaceutical forms that potentiate the bioavailability of 18?-GA, having a high permeation on the application area mainly due to the effect of their small particle size, high concentration of the active ingredient, excipient composition, micelles with specific structural composition and polarity. The present pharmaceutical forms exhibit specific values for particle size, permeability, diffusion coefficient, and polydispersity helping to provide its technical advantages. Therapeutic uses of the pharmaceutical forms are also described, which include those therapeutic uses for which 18?-glycyrrhetinic acid is known to have an effect, such as anti-inflammatory, antiviral, antibacterial activity, hepatoprotective, used against skin diseases and anticarcinogenic.